Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2587450 | 0.82 | P2RX7 (0.38) | P2RX7HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL2575522 | 0.82 | P2RX7 (0.38) | P2RX7HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL5139123 | 0.79 | P2RX7 (0.32) | P2RX7HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL2585902 | 0.79 | P2RX7 (0.32) | P2RX7HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL2578467 | 0.78 | HCRTR1 (0.32) | P2RX7HCRTR1HCRTR2PARP1MEN1 | |
| SCHEMBL4088718 | 0.77 | P2RX7 (0.38) | P2RX7MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL2577904 | 0.77 | P2RX7 (0.33) | P2RX7MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4521091 | 0.75 | ALDH1A1 (0.41) | HCRTR1HCRTR2MEN1KMT2AALDH1A1 | |
| SCHEMBL4521089 | 0.75 | ALDH1A1 (0.41) | HCRTR1HCRTR2MEN1KMT2AALDH1A1 | |
| SCHEMBL2578323 | 0.74 | HCRTR1 (0.34) | P2RX7HCRTR1HCRTR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8048878-B2 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | P2RX7 1836/4885HCRTR1 753/4885HCRTR2 539/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | P2RX7 1836/4885HCRTR1 753/4885HCRTR2 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.